Literature DB >> 7008587

Hematologic alterations in diabetes mellitus.

R L Jones, C M Peterson.   

Abstract

Several hematologic abnormalities have been defined in patients with diabetes mellitus, despite the lack of classic hematologic pathologic findings in this condition. Studies of the erythrocyte and the formation of hemoglobin A1c have provided a means of documenting glycemia and a model reaction for diabetic sequelae through postsynthetic protein modification. Oxygen affinity has been noted to be abnormal in the diabetic erythrocyte, concomitant with a decreased concentration of inorganic phosphorus, glycosylation of the 2,3-diphosphoglycerate binding site or preexisting vascular disease. Red cell membrane viscosity has also been documented to be increased in the hyperglycemic subject. Abnormalities in the polymorphonuclear leukocyte have been described, involving the properties of adherence, random migration, chemotaxis, phagocytosis and killing. Certain metabolic abnormalities are also present in this cell type. The lymphocyte has been shown to have abnormal metabolic properties, mitogen responses and cell surface properties in diabetes both in animals and human subjects. Certain subpopulations of lymphocytes appear to be especially vulnerable to changes concomitant with diabetes mellitus. In vitro abnormalities of platelet behavior have been widely studied, although the in vivo significance of these findings remains controversial. Studies of the fluid phase of coagulation have suggested the existence of a hypercoagulable state in hyperglycemic subjects. The clinical significance of most of these findings remains to be defined. Nevertheless, the observation that many of the abnormalities described are reversible when hyperglycemia is corrected has given impetus to the development of improved systems of glucose "control" for diabetic patients.

Entities:  

Mesh:

Year:  1981        PMID: 7008587     DOI: 10.1016/0002-9343(81)90771-3

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  30 in total

1.  Controlling blood sugars.

Authors:  A Mehta; I Matwijiw
Journal:  Can Fam Physician       Date:  1985-07       Impact factor: 3.275

2.  Non-insulin dependent diabetes and ischaemic heart disease.

Authors:  J T Salonen
Journal:  BMJ       Date:  1989-04-22

3.  Beta-thromboglobulin and fibrinopeptide A in diabetes mellitus as markers of vascular damage.

Authors:  M C Librenti; A D'Angelo; P Micossi; B Garimberti; P M Mannucci; G Pozza
Journal:  Acta Diabetol Lat       Date:  1985 Jan-Mar

4.  Platelet sensitivity in vitro to adenosine-5'-diphosphate and prostacyclin and diabetic retinopathy.

Authors:  T M Davis; E Bown; R C Turner
Journal:  Diabetologia       Date:  1985-05       Impact factor: 10.122

Review 5.  Anaemia in diabetes: Is there a rationale to TREAT?

Authors:  M C Thomas; M E Cooper; K Rossing; H H Parving
Journal:  Diabetologia       Date:  2006-04-04       Impact factor: 10.122

Review 6.  Coagulation activation in diabetes mellitus: the role of hyperglycaemia and therapeutic prospects.

Authors:  A Ceriello
Journal:  Diabetologia       Date:  1993-11       Impact factor: 10.122

Review 7.  Erythropoietic stress and anemia in diabetes mellitus.

Authors:  Dhruv K Singh; Peter Winocour; Ken Farrington
Journal:  Nat Rev Endocrinol       Date:  2009-04       Impact factor: 43.330

8.  Metabolite differences in the lenticular nucleus in type 2 diabetes mellitus shown by proton MR spectroscopy.

Authors:  Y Lin; J Zhou; L Sha; Y Li; X Qu; L Liu; H Chen; Z An; Y Wang; C Sun
Journal:  AJNR Am J Neuroradiol       Date:  2013-04-18       Impact factor: 3.825

9.  Increased single strand breaks in DNA of lymphocytes from diabetic subjects.

Authors:  M Lorenzi; D F Montisano; S Toledo; H C Wong
Journal:  J Clin Invest       Date:  1987-02       Impact factor: 14.808

10.  Antioxidant enzyme alterations in experimental and clinical diabetes.

Authors:  D V Godin; S A Wohaieb; M E Garnett; A D Goumeniouk
Journal:  Mol Cell Biochem       Date:  1988-12       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.